Amgen’s second quarter results outpaced Wall Street’s expectations, with management emphasizing strong demand for its ...

US Dollar South African Rand, Nasdaq 100, S&P 500, Intel Corporation. Read 's Market Analysis on Investing.com ZA.

Experts outline AE risks—including ICANS, CRS, HLH—as T-cell engager use expands, highlighting the crucial role of nurses and ...

AMGN posts strong Q2 results as Repatha, Evenity, Blincyto and rare disease drugs power broad-based volume gains.

Q2 2025 Earnings Call Transcript August 5, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $6.02, expectations ...

Amgen Inc (NASDAQ:AMGN) shares were slightly lower in premarket trading despite posting better-than-expected quarterly profit ...

Amgen reported total revenue of $9.2 billion, topping the consensus of $8.9 billion, and non-GAAP earnings of $6.02 per share ...

Amgen Inc (NASDAQ:AMGN) saw a modest decline in premarket trading even after reporting quarterly profit and revenue results ...

Non-GAAP earnings per share for Q2 2025 beat estimates by 14.0%, rising to $6.02 (non-GAAP) and up 21% year over year (non-GAAP). Revenue increased 9% to $9.2 billion, exceeding analyst expectations ...

Amgen’s diversified portfolio strategy continues to hinge on a balance between high-margin legacy biologics, expanding biosimilar offerings, and innovative pipeline investments. Repatha and BLINCYTO ...

Fifteen of the biotechnology company’s products delivered at least double-digit sales growth in the second quarter including Repatha, Evenity and Imdelltra.